Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 56

1.

From big data to smart data in Alzheimer's disease. The brain health modeling initiative to foster actionable knowledge.

Geerts H, Dacks PA, Devanarayan V, Haas M, Khatchaturian Z, Gordon MF, Maudsley S, Romero K, Stephenson D; Brain Health Modeling Initiative (BHMI).

Alzheimers Dement. 2016 May 26. pii: S1552-5260(16)30246-1. doi: 10.1016/j.jalz.2016.04.008. [Epub ahead of print] Review.

2.

Age-Stratified Prevalence of Mild Cognitive Impairment and Dementia in European Populations: A Systematic Review.

Alexander M, Perera G, Ford L, Arrighi HM, Foskett N, Debove C, Novak G, Gordon MF.

J Alzheimers Dis. 2015;48(2):355-9. doi: 10.3233/JAD-150168.

PMID:
26401999
3.

Current Developments in Dementia Risk Prediction Modelling: An Updated Systematic Review.

Tang EY, Harrison SL, Errington L, Gordon MF, Visser PJ, Novak G, Dufouil C, Brayne C, Robinson L, Launer LJ, Stephan BC.

PLoS One. 2015 Sep 3;10(9):e0136181. doi: 10.1371/journal.pone.0136181. eCollection 2015. Review.

4.

Development of a patient-reported outcome instrument to assess complex activities of daily living and interpersonal functioning in persons with mild cognitive impairment: The qualitative research phase.

Gordon MF, Lenderking WR, Duhig A, Chandler J, Lundy JJ, Miller DS, Piault-Louis E, Doody RS, Galasko D, Gauthier S, Frank L; Patient-Reported Outcome Consortium's Cognition Working Group.

Alzheimers Dement. 2016 Jan;12(1):75-84. doi: 10.1016/j.jalz.2015.04.008. Epub 2015 Jun 13. Review.

PMID:
26079412
5.

Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.

Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, Visser PJ; Amyloid Biomarker Study Group, Aalten P, Aarsland D, Alcolea D, Alexander M, Almdahl IS, Arnold SE, Baldeiras I, Barthel H, van Berckel BN, Bibeau K, Blennow K, Brooks DJ, van Buchem MA, Camus V, Cavedo E, Chen K, Chetelat G, Cohen AD, Drzezga A, Engelborghs S, Fagan AM, Fladby T, Fleisher AS, van der Flier WM, Ford L, Förster S, Fortea J, Foskett N, Frederiksen KS, Freund-Levi Y, Frisoni GB, Froelich L, Gabryelewicz T, Gill KD, Gkatzima O, Gómez-Tortosa E, Gordon MF, Grimmer T, Hampel H, Hausner L, Hellwig S, Herukka SK, Hildebrandt H, Ishihara L, Ivanoiu A, Jagust WJ, Johannsen P, Kandimalla R, Kapaki E, Klimkowicz-Mrowiec A, Klunk WE, Köhler S, Koglin N, Kornhuber J, Kramberger MG, Van Laere K, Landau SM, Lee DY, de Leon M, Lisetti V, Lleó A, Madsen K, Maier W, Marcusson J, Mattsson N, de Mendonça A, Meulenbroek O, Meyer PT, Mintun MA, Mok V, Molinuevo JL, Møllergård HM, Morris JC, Mroczko B, Van der Mussele S, Na DL, Newberg A, Nordberg A, Nordlund A, Novak GP, Paraskevas GP, Parnetti L, Perera G, Peters O, Popp J, Prabhakar S, Rabinovici GD, Ramakers IH, Rami L, Resende de Oliveira C, Rinne JO, Rodrigue KM, Rodríguez-Rodríguez E, Roe CM, Rot U, Rowe CC, Rüther E, Sabri O, Sanchez-Juan P, Santana I, Sarazin M, Schröder J, Schütte C, Seo SW, Soetewey F, Soininen H, Spiru L, Struyfs H, Teunissen CE, Tsolaki M, Vandenberghe R, Verbeek MM, Villemagne VL, Vos SJ, van Waalwijk van Doorn LJ, Waldemar G, Wallin A, Wallin ÅK, Wiltfang J, Wolk DA, Zboch M, Zetterberg H.

JAMA. 2015 May 19;313(19):1924-38. doi: 10.1001/jama.2015.4668.

6.

Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop.

Romero K, Sinha V, Allerheiligen S, Danhof M, Pinheiro J, Kruhlak N, Wang Y, Wang SJ, Sauer JM, Marier JF, Corrigan B, Rogers J, Lambers Heerspink HJ, Gumbo T, Vis P, Watkins P, Morrison T, Gillespie W, Gordon MF, Stephenson D, Hanna D, Pfister M, Lalonde R, Colatsky T.

J Pharmacokinet Pharmacodyn. 2014 Dec;41(6):545-52. doi: 10.1007/s10928-014-9390-0. Epub 2014 Oct 7.

PMID:
25288257
7.

The efficacy and safety of pramipexole ER versus IR in Chinese patients with Parkinson's disease: a randomized, double-blind, double-dummy, parallel-group study.

Wang Y, Sun S, Zhu S, Liu C, Liu Y, Di Q, Shang H, Ren Y, Lu C, Gordon MF, Juhel N, Chen S.

Transl Neurodegener. 2014 Jun 2;3:11. doi: 10.1186/2047-9158-3-11. eCollection 2014.

8.

Impact of disclosure of individual imaging results in a multi-center Parkinson clinical trial.

Jennings D, Eberly S, Oakes D, Seibyl J, Marek K, Shoulson I; Parkinson Study Group PRECEPT Investigators.

J Parkinsons Dis. 2014;4(4):629-38. doi: 10.3233/JPD-140383.

PMID:
25062961
9.

Minimal clinically important difference in Parkinson's disease as assessed in pivotal trials of pramipexole extended release.

Hauser RA, Gordon MF, Mizuno Y, Poewe W, Barone P, Schapira AH, Rascol O, Debieuvre C, Fräßdorf M.

Parkinsons Dis. 2014;2014:467131. doi: 10.1155/2014/467131. Epub 2014 Apr 1.

10.

Importance and hurdles to drug discovery for neurological disease.

Berger JR, Choi D, Kaminski HJ, Gordon MF, Hurko O, D'Cruz O, Pleasure SJ, Feldman EL.

Ann Neurol. 2013 Sep;74(3):441-6. doi: 10.1002/ana.23997. Review.

PMID:
25813523
11.

Predictors of placebo response in restless legs syndrome studies.

Ondo WG, Hossain MM, Gordon MF, Reess J.

Neurology. 2013 Jul 9;81(2):193-4. doi: 10.1212/WNL.0b013e31829a33bd. Epub 2013 Jun 7. No abstract available.

PMID:
23749799
12.

Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease.

Schwid SR, Bausch J, Oakes D, Schuchter L, Tanner C, Forrest M, Lang AE, Shoulson I; PSG PRECEPT Investigators, Shoulson I, Hyson C, Oakes D, Flagg E, Rudolph A, Kieburtz K, Lang A, Fahn S, Gauger L, Goetz C.

Mov Disord. 2010 Sep 15;25(12):1801-8. doi: 10.1002/mds.23006.

PMID:
20669311
13.

A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts.

Marras C, Lang AE, Eberly SW, Oakes D, Fahn S, Schwid SR, Hyson C, Shoulson I; Parkinson Study Group DATATOP and PRECEPT investigators.

Mov Disord. 2009 Dec 15;24(16):2370-8. doi: 10.1002/mds.22828.

PMID:
19908310
14.

Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.

Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, Fitzer-Attas CJ; TEMPO Open-label Study Group.

Mov Disord. 2009 Mar 15;24(4):564-73. doi: 10.1002/mds.22402.

PMID:
19086083
15.

Interprofessional capability: A developing framework for interprofessional education.

Walsh CL, Gordon MF, Marshall M, Wilson F, Hunt T.

Nurse Educ Pract. 2005 Jul;5(4):230-7. doi: 10.1016/j.nepr.2004.12.004.

PMID:
19038204
16.

Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease.

White WB, Salzman P, Schwid SR; Parkinson's Rasagiline: Efficacy and Safety in the Treatment of Off Parkinson Study Group.

Hypertension. 2008 Sep;52(3):587-93. doi: 10.1161/HYPERTENSIONAHA.108.115873. Epub 2008 Aug 4.

17.

Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay.

Brin MF, Comella CL, Jankovic J, Lai F, Naumann M; CD-017 BoNTA Study Group.

Mov Disord. 2008 Jul 30;23(10):1353-60. doi: 10.1002/mds.22157.

PMID:
18546321
18.

Serum urate as a predictor of clinical and radiographic progression in Parkinson disease.

Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, Shoulson I, Ascherio A; Parkinson Study Group PRECEPT Investigators, Hyson C, Gorbold E, Rudolph A, Kieburtz K, Fahn S, Gauger L, Goetz C, Seibyl J, Forrest M, Ondrasik J.

Arch Neurol. 2008 Jun;65(6):716-23. doi: 10.1001/archneur.2008.65.6.nct70003. Epub 2008 Apr 14.

19.

Relationship between self-reported apathy and executive dysfunction in nondemented patients with Parkinson disease.

Zgaljardic DJ, Borod JC, Foldi NS, Rocco M, Mattis PJ, Gordon MF, Feigin AS, Eidelberg D.

Cogn Behav Neurol. 2007 Sep;20(3):184-92.

20.

Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials.

Yablon SA, Brashear A, Gordon MF, Elovic EP, Turkel CC, Daggett S, Liu J, Brin MF.

Clin Ther. 2007 Apr;29(4):683-90.

PMID:
17617291
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk